English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Acinetobacter baumannii  is responsible for 10% of all nosocomial infections and has >50% mortality rates when causing ventilator-associated pneumonia. In this proof-of-concept study, we evaluated SPR741, an antibiotic adjuvant that permeabilizes the Gram-negative membrane, in combination with rifampin against AB5075, an extensively drug-resistant (XDR)  A. baumannii  strain. In standard  in vitro  assays and in a murine pulmonary model, we found that this drug combination can significantly reduce bacterial burden and promote animal survival despite an aggressive infection.

antimicrobial agents and chemotherapy

SPR741, an Antibiotic Adjuvant, Potentiates the<i>In Vitro</i>and<i>In Vivo</i>Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii

SPR741, an Antibiotic Adjuvant, Potentiates theIn VitroandIn VivoActivity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii